Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Outside Perspectives Beget Better Outcomes

Posted on January 26th, 2016 by

Pharma R&D

theory_wide-c844f178048a2684625fb1a1fb5c4c4e42fc124a-s6-c30

My favorite quote about why drug discovery, despite very productive decades of productivity and innovation, has seemed to have reached the drought is from Ashutosh Jogalekar in Scientific American blog: (more…)

Gender gap, the leaking pipeline of R&D

Posted on January 21st, 2016 by

Pharma R&D

R_D_Solutions_blog_mind_the_gap_DIGITAL

I guess we all worked out that half of the people on this planet are male and the other half are female. If you even sporadically read the papers you must have stumbled upon some sort of article quoting numbers such as (more…)

EMA Yearly Update on MLM – highlights and next steps

Posted on January 19th, 2016 by

Pharmacovigilance

pills

EMA  Pharmacovigilance Programme Update Issue 6 – Preparing for Business Change

Since July 2014, EMA provides quarterly Pharmacovigilance Programme Updates to Marketing Authorisation Holders (MAHs). (more…)

Unmixing the messages

Posted on January 18th, 2016 by

Pharma R&D

R_D_Solutions_Blog_Image_Cars_DIGITAL

Have you ever driven through a red light because you were looking at the wrong traffic signal? Or had a row of angry motorists behind you because you hadn’t realized the signal above your lane had turned green? (more…)

Monitoring literature for Benefit-Risk Evaluation: a Life-Time Responsibility

Posted on January 15th, 2016 by

Pharmacovigilance

Medical Literature

Monitoring worldwide experience

The purpose of drugs is to cure or alleviate symptoms of disease. However, drugs do not only have therapeutic effects, they may also cause adverse drug reactions (ADRs). (more…)

Does improving pre-clinical research reduce late-stage failures and improve R&D productivity?

Posted on January 12th, 2016 by

Pharma R&D

R_D_Solutions_blog_image_male_female_researchers_DIGITAL

It’s the turn of the year and if you’re like me, you’ve been immersed in reading all of the accompanying look back and look ahead articles and reports. 2015 was, indeed, a notable year — from the Martin Shkreli fiasco to the proposed Pfizer and Allergan merger — the industry was rocked. (more…)

  1. 1
  2. 57
  3. 58
  4. 59
  5. 60
  6. 61
  7. 64


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.